A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and ...

New research suggests that electrical spinal cord stimulation could improve muscle function for patients who have spinal ...

Liver issues, including a buildup of fat in the liver, occur before the onset of neuromuscular disease, per a study in a mouse model of SMA.

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...

BACKGROUND: Spinal Muscular Atrophy (SMA) is a group of genetic disorders characterized by the degeneration of motor neurons in the spinal cord and brainstem, leading to muscle weakness and atrophy.

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started reviewing a higher dose regimen of its spinal muscular atrophy ... motor neuron ...